Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation
Céline Augé, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Magnus Grabe
Objective: Inflammation of the urinary bladder may cause burdensome pain also called bladder pain syndrome (BPS). A limitation in understanding BPS pathophysiology is the lack of appropriate preclinical model. Previously published clinical and preclinical studies revealed positive impact of CernitinTM on pain relief in chronic prostatitis. The objective of this study was to evaluate the effects of CernitinTM on induced inflammation of the urinary bladder in rats. We also sought to identify biomarkers which might play a role in the management of BPS.
Impact of Cernitin TM on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms
Sophie Chabot, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Per-Anders Abrahamsson, Magnus Grabe
Background: Cernitin TM pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin TM induce a regulatory effect on inflammatory parameters.
Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin TM in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay.
The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: An in vitro study
Nishtman Dizeyi, Ingrid Yao Mattisson, Lena Ramnemark, Magnus Grabe4, Per‐Anders Abrahamsson
The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non‐bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH‐1 and WPMY‐1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production.
Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Giuseppe Magistro, Florian M.E. Wagenlehner, Magnus Grabe, Wolfgang Weidner, Christian G. Stief, J. Curtis Nickel
Context: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition that causes severe symptoms, bother, and quality-of-life impact in the 8.2% of men who are believed to be affected. Research suggests a complex pathophysiology underlying this syndrome that is mirrored by its heterogeneous clinical presentation. Management of patients diagnosed with CP/CPPS has always been a formidable task in clinical practice. Due to its enigmatic etiology, a plethora of clinical trials failed to identify an efficient monotherapy.
Cernilton in Patients with Inflammatory Chronic Prostatitis–Chronic Pelvic Pain Syndrome
Florian M.E. Wagenlehner, Henning Schneider, Martin Ludwig, Jörg Schnitker, Elmar Brähler, Wolfgang Weidner
A Pollen Extract (Cernilton) in Patients with Inflammatory Chronic Prostatitis–Chronic Pelvic Pain Syndrome: A Multicentre, Randomised, Prospective, Double-Blind, Placebo-Controlled Phase 3 Study.
Background: National Institutes of Health (NIH) category III prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent condition for which no standardised treatment exists.
Objectives: To assess the safety and efficacy of a standardised pollen extract in men with inflammatory CP/CPPS.